Daniel P Petrylak

Daniel P Petrylak is affiliated with the Yale Cancer Center.[1]He specializes in urology and medicine.[23]He is a member of Signal Transduction Research Program.[4]

Daniel P. Petrylak, MD, is professor of medicine and professor of urology at Yale School of Medicine and co-director of the Signal Transduction Research Program at Yale Cancer Center.[5]He is the head of the advanced bladder subcommittee in the Southwest Oncology Group Genitourinary Committee.[5]Most notably, he served as the PI for a randomized trial comparing docetaxel and estramustine with mitoxantrone and prednisone in men with hormone-refractory prostate cancer.[5]He graduated from Columbia College in New York and earned his medical degree from Case Western Reserve University of Medicine in Cleveland, Ohio.[6]He has authored or co-authored more than 100 articles and abstracts in peer-reviewed journals as Cancer, Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Journal of the National Cancer Institute, Journal of Urology, Nature and New England Journal of Medicine.[6]He has also served as a member of the U.S. Food and Drug Administration Immunology Devices Advisory Committee.[6]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Daniel P Petrylak on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.

Yale Cancer Center


  • 4


  • 346


  • 95


Recent events

Daniel Petrylak, EMSO 2019 – Phase III KEYNOTE-321 study in prostate cancer

We met Daniel Petrylak at EMSO 2019 to discuss results from the phase III KEYNOTE-921 study. KEYNOTE-921 is a study of pembrolizumab plus docetaxel and prednisone in abiraterone or enzalutamide-pretreated patients with metastatic castrate resistant prostate cancer.[7]


Event Date

ASCO 2019: New Agent Targets Metastatic Bladder Cancer

In describing results of treatment with enfortumab vedotin, Daniel Petrylak, MD, professor of medicine and urology at the Yale Cancer Center, New Haven, Connecticut, said that 12% of patients treated with the agent achieved a complete response and 32% of the 125 patients in the study achieved a RECIST-confirmed partial response. “We have Phase 3 trials comparing enfortumab vedotin with standard chemotherapy in urothelial cancer and we are also combining it with checkpoint inhibitors,” Petrylak said.[8]


Event Date

Yale Cancer Center presents Research awards during annual Conclave

Barbara Burtness, M.D., and Daniel Petrylak, M.D., were each presented with the YCC Clinical Science Research Award. Burtness is a Professor of Medicine, Leader of the Disease Aligned Research Team for Smilow Cancer Hospital at Yale New Haven’s Head & Neck Cancers Program and Co-Leader of the Developmental Therapeutics Research Program at YCC. Chen is the United Technologies Corporation Professor in Cancer Research, a Professor of Immunobiology, of Dermatology and of Medicine, and Co-Leader for the Cancer Immunology Resesarch Program at YCC.[9]


Event Date